×
Zoetis Revenue 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Zoetis revenue for the twelve months ending September 30, 2024 was
$9.152B
, a
9.33% increase
year-over-year.
Zoetis annual revenue for 2023 was
$8.544B
, a
5.74% increase
from 2022.
Zoetis annual revenue for 2022 was
$8.08B
, a
3.91% increase
from 2021.
Zoetis annual revenue for 2021 was
$7.776B
, a
16.49% increase
from 2020.
View More
Zoetis Revenue 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Zoetis annual revenue for 2023 was
$8.544B
, a
5.74% increase
from 2022.
Zoetis annual revenue for 2022 was
$8.08B
, a
3.91% increase
from 2021.
Zoetis annual revenue for 2021 was
$7.776B
, a
16.49% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$66.9B
Takeda Pharmaceutical (TAK)
$42.4B
Sandoz Group AG (SDZNY)
$20.6B
Merck (MKKGY)
$20B
Astellas Pharma (ALPMY)
$17.7B
United Therapeutics (UTHR)
$16.6B
Summit Therapeutics (SMMT)
$16B
Neurocrine Biosciences (NBIX)
$15.3B
Shionogi (SGIOY)
$12.5B
Orion OYJ (ORINY)
$7.5B
Madrigal Pharmaceuticals (MDGL)
$7.1B
Stevanato Group S.p.A (STVN)
$6.5B
Corcept Therapeutics (CORT)
$6.4B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ionis Pharmaceuticals (IONS)
$5.2B
Ono Pharmaceutical (OPHLF)
$4.9B
Grifols, S.A (GRFS)
$4.8B
Crinetics Pharmaceuticals (CRNX)
$3.7B
Catalyst Pharmaceuticals (CPRX)
$2.9B
Recursion Pharmaceuticals (RXRX)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Centessa Pharmaceuticals (CNTA)
$2.2B
Soleno Therapeutics (SLNO)
$2.1B
Hypermarcas (HYPMY)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.9B
Indivior (INDV)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.7B
Evotec AG (EVO)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.4B
ARS Pharmaceuticals (SPRY)
$1.4B